Neurocrine Biosciences and Takeda Pharmaceutical have announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.
According to Neurocrine, this partnership enhances its growing pipeline and strengthens its position as a neuroscience-focused biopharmaceutical company. The company brings experience developing and commercializing therapies for serious neurological and psychiatric disorders to the partnership.
Under the terms of the agreement, Neurocrine Biosciences will be responsible for developing and commercializing all pipeline compounds included in the collaboration. Takeda will receive a total of $120 million in upfront cash. Takeda will be entitled to development milestones of up to $495 million, commercial milestones of up to $1.4 billion and up to double-digit royalties on net sales. At certain development events, Takeda may elect to opt in or out of a 50:50 profit share on all clinical programs on an asset-by-asset basis. For any asset in which Takeda is participating in a 50:50 profit share arrangement, Takeda will not be eligible to receive development or commercial milestones.
Read the Neurocrine Biosciences release